PH Pharma, which develops a treatment for glaucoma and non-alcoholic steatohepatitis (NASH), is conducting a pre-IPO (attracting funds before listing) worth 15 billion won. It is a form of large-scale purchase of new stocks (including preferred stocks) by domestic securities companies and management companies. The final goal is to be listed on the KOSDAQ within this year. The key point is whether the license out (RO) to a Chinese company is realized.
(For more information, please refer to the link below)